Nanoformulations for combination or cascade anticancer therapy
Nanoparticle drug formulations have been extensively investigated, developed, and in some
cases, approved by the Food and Drug Administration (FDA). Synergistic combinations of
drugs having distinct tumor-inhibiting mechanisms and non-overlapping toxicity can
circumvent the issue of treatment resistance and may be essential for effective anti-cancer
therapy. At the same time, co-delivery of a combined regimen by a single nanocarrier
presents a challenge due to differences in solubility, molecular weight, functional groups …
cases, approved by the Food and Drug Administration (FDA). Synergistic combinations of
drugs having distinct tumor-inhibiting mechanisms and non-overlapping toxicity can
circumvent the issue of treatment resistance and may be essential for effective anti-cancer
therapy. At the same time, co-delivery of a combined regimen by a single nanocarrier
presents a challenge due to differences in solubility, molecular weight, functional groups …
Abstract
Nanoparticle drug formulations have been extensively investigated, developed, and in some cases, approved by the Food and Drug Administration (FDA). Synergistic combinations of drugs having distinct tumor-inhibiting mechanisms and non-overlapping toxicity can circumvent the issue of treatment resistance and may be essential for effective anti-cancer therapy. At the same time, co-delivery of a combined regimen by a single nanocarrier presents a challenge due to differences in solubility, molecular weight, functional groups and encapsulation conditions between the two drugs. This review discusses cellular and microenvironment mechanisms behind treatment resistance and nanotechnology-based solutions for effective anti-cancer therapy. Co-loading or cascade delivery of multiple drugs using of polymeric nanoparticles, polymer-drug conjugates and lipid nanoparticles will be discussed along with lipid-coated drug nanoparticles developed by our lab and perspectives on combination therapy.
Elsevier